In re Copley Pharmaceutical, Inc.

161 F.R.D. 456, 1995 U.S. Dist. LEXIS 5578, 1995 WL 247682
CourtDistrict Court, D. Wyoming
DecidedApril 25, 1995
DocketMDL No. 1013
StatusPublished
Cited by31 cases

This text of 161 F.R.D. 456 (In re Copley Pharmaceutical, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Wyoming primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Copley Pharmaceutical, Inc., 161 F.R.D. 456, 1995 U.S. Dist. LEXIS 5578, 1995 WL 247682 (D. Wyo. 1995).

Opinion

ORDER DENYING DEFENDANT’S MOTION TO DECERTIFY THE CLASS AND THE COURT’S TRIAL PLAN

BRIMMER, District Judge.

The above-entitled matter comes before the Court on the Defendant’s Motion to De-certify the Class and the Plaintiffs’ opposition thereto, and the trial plans submitted by the parties, and the Court, having reviewed the relevant materials on file herein, having heard the oral arguments of the parties and being fully informed in the premises, FINDS and ORDERS as follows:

Background

This case involves a national class action product liability lawsuit against Defendant Copley Pharmaceutical, Inc. A history of the case can be found in the Court’s Order Granting Partial Class Certification. In re Copley Pharmaceutical, Inc., 158 F.R.D. 485 (D.Wyo.1994). Copley manufactures generic drugs including Albuterol, a bronchodilator prescription pharmaceutical. Copley’s Albu-terol was the subject of a nationwide recall in January 1994 after contamination was discovered in its Albuterol 0.5% solution. The exact nature, cause and extent of this contamination remains the subject of much controversy and is one of the issues pending before this Court.

Following the recall, Copley was named in a large number of lawsuits filed throughout the United States. Ultimately the Judicial Panel on Multidistrict Litigation consolidated all the federal cases brought against Copley in this Court. On July 18, 1994, this Court held an initial status conference in which it appointed a Plaintiffs’ Steering Committee [458]*458(PSC) to coordinate discovery with Copley. The PSC, with some dissention from other plaintiffs’ counsel, filed an Amended Class Action Complaint and asked the Court to certify the case of Holmes, et al. v. Copley, 94-MD-1503 as a class action.

On October 28, 1994, the Court issued its Order Granting Partial Class Certification. See In re Copley, supra. In that Order the Court recognized the presence of several common threshold issues affecting the class:

(1) Were the Defendant’s manufacturing processes defective?
(2) Was the Defendant negligent in its manufacture and distribution of Albuter-ol?
(3) Did the Defendant breach any warranties in selling its product? and,
(4) Are pseudomonas fluorescens or other possible contaminants dangerous to the human body?

Id. at 489. The Court also held that individual issues of causation and damages were present and that those issues were not proper for class adjudication. Id. at 492. Balancing these considerations under Fed. R.Civ.P. 23(c)(4)(A), the Court certified the class under Fed.R.Civ.P. 23(b)(3) for the following common issues of liability: strict liability, negligence, negligence per se, breach of warranties, and declaratory relief. Id. at 493.

The Court’s approach was influenced, in part, by a similar holding by Judge Grady in his certification of another partial class action brought by hemophiliacs against blood products manufacturers. See, Wadleigh v. Rhone-Poulenc Rorer, Inc., et al., 157 F.R.D. 410 (N.D.Ill.1994). In the intervening six and a half months, Copley neither appealed this Court’s class certification nor moved for reconsideration.

Subsequent to the class certification, this action has moved forward with surprising speed and efficiency. For the most part, counsel on both sides have cooperated to coordinate discovery and minimize the delays that can plague national products liability actions. See, e.g. In re School Asbestos Litigation, 789 F.2d 996 (3d Cir.1986), cert. denied, 479 U.S. 915, 107 S.Ct. 318, 93 L.Ed.2d 291 (1986). In fact, discovery has continued even though Copley has become the focus of a grand jury investigation in Massachusetts. Plaintiffs and the Defendant have cooperated to provide notice to the class, and those wishing to opt-out did so prior to March 15, 1995. Currently the matter is set for a final pretrial conference on May 30,1995, and trial is scheduled for June 12, 1995.

Pursuant to Management Order Number Six, the parties submitted their trial plans on April 17,1995. These plans will be discussed in more detail below. Along with its trial plan, Copley filed the pending Motion to Decertify the Class. In that motion, Copley argues that the Court should decertify the class because the Seventh Circuit reversed Judge Grady’s class certification in Wad-leigh. See, In re Rhone-Poulenc Rorer Inc., et al., 51 F.3d 1293 (7th Cir.1995). Based largely on that decision, Copley has submitted two arguments for class decertification. First, Copley contends that its Seventh Amendment rights will be infringed by the Court’s bifurcated trial plan. Second, Copley argues that the class is unmanageable because it is impossible for the Court to consider the laws of fifty-one different jurisdictions. Plaintiffs argue in reply that the class certified by the Court is not only constitutional and manageable, but is also the fairest way to resolve the common issues facing the class. Plaintiffs also suggest that the Defendant’s motion is motivated by a desire to dissipate the resources of the Plaintiffs, thereby preventing many of them from pursuing claims.

The Court held a hearing on the motion and the trial plans oh April 21, 1995. After careful consideration of Copley’s arguments, the Rhone-Poulenc decision, and the Court’s fiduciary duty to the class, the Court is confident that its class certification remains legally sound. In its October order the Court noted the difficulty in deciding whether to certify the class at that early stage of the litigation. In re Copley, 158 F.R.D. at 488. After dealing with this class through many more hours of hearings over the last seven months, the Court is even more convinced that the class certification of some common issues is necessary and judicially efficient.

[459]*459 I. Defendant Copley’s Motion to Decertify the Class

As mentioned above, Copley’s motion to decertify makes two arguments: (1) the Seventh Amendment precludes submitting the elements of liability to separate juries, and (2) a trial would be unmanageable because the Court would be required to apply the differing laws of all fifty states. It is clear from the tone and substance of these arguments that they are inspired by the decision in In re Rhone-Poulenc,1 Therefore, the Court examines In re Rhone-Poulenc to explore its applicability to this case.

A. In re Rhone-Poulenc Rorer, Inc., et al.

In Wadleigh, et al. v. Rhone-Poulenc Rorer, Inc., 157 F.R.D. 410 (N.D.Ill.1994), the United States District Court for the Northern District of Illinois certified a partial class of hemophiliacs for their claims against four different suppliers of blood products.2 The basis of the plaintiffs’ claim in Wadleigh

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cooney v. Rossiter
2012 IL 113227 (Illinois Supreme Court, 2013)
Donovan v. Philip Morris USA, Inc.
268 F.R.D. 1 (D. Massachusetts, 2010)
City of St. Petersburg v. Total Containment, Inc.
265 F.R.D. 630 (S.D. Florida, 2010)
In re Live Concert Antitrust Litigation
247 F.R.D. 98 (C.D. California, 2007)
Sweet v. Pfizer
232 F.R.D. 360 (C.D. California, 2005)
In re Baycol Products Litigation
218 F.R.D. 197 (D. Minnesota, 2003)
Liggett Group, Inc. v. Engle
853 So. 2d 434 (District Court of Appeal of Florida, 2003)
Henry Schein, Inc. v. Stromboe
102 S.W.3d 675 (Texas Supreme Court, 2002)
In re Simon II Litigation
211 F.R.D. 86 (E.D. New York, 2002)
Rink v. Cheminova, Inc.
203 F.R.D. 648 (M.D. Florida, 2001)
Robinson v. Metro-North Commuter R.R. Co.
267 F.3d 147 (Second Circuit, 2001)
Robinson v. Metro-North Commuter Railroad
267 F.3d 147 (Second Circuit, 2001)
Simon v. Philip Morris Inc.
200 F.R.D. 21 (E.D. New York, 2001)
Wash. Mut. Bank v. Superior Court of Orange Cty.
15 P.3d 1071 (California Supreme Court, 2001)
Cook v. Rockwell International Corp.
181 F.R.D. 473 (D. Colorado, 1998)
Fisher v. Bristol-Myers Squibb Co.
181 F.R.D. 365 (N.D. Illinois, 1998)
In Re Copley Pharmaceutical, Inc.
1 F. Supp. 2d 1407 (D. Wyoming, 1998)
Burns v. Copley Pharmaceuticals, Inc.
132 F.3d 42 (Tenth Circuit, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
161 F.R.D. 456, 1995 U.S. Dist. LEXIS 5578, 1995 WL 247682, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-copley-pharmaceutical-inc-wyd-1995.